相似文献
1
New therapeutic options in the management of COPD - focus on roflumilast.
Int J Chron Obstruct Pulmon Dis. 2011;6:147-55. doi: 10.2147/COPD.S7336. Epub 2011 Feb 17.
2
[Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
Arch Bronconeumol. 2010 Nov;46 Suppl 9:8-11. doi: 10.1016/S0300-2896(10)70047-8.
3
Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Respir Res. 2011 Jan 27;12(1):18. doi: 10.1186/1465-9921-12-18.
4
Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA.
Int J Chron Obstruct Pulmon Dis. 2018 May 3;13:1455-1468. doi: 10.2147/COPD.S159827. eCollection 2018.
5
The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. doi: 10.1016/j.pupt.2010.03.011. Epub 2010 Apr 7.
6
Roflumilast for the treatment of chronic obstructive pulmonary disease.
Expert Rev Respir Med. 2010 Oct;4(5):543-55. doi: 10.1586/ers.10.56.
7
[Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].
Dtsch Med Wochenschr. 2011 Nov;136(44):2267-70. doi: 10.1055/s-0031-1292040. Epub 2011 Oct 25.
8
Roflumilast for COPD.
Drugs Today (Barc). 2010 Nov;46(11):823-31. doi: 10.1358/dot.2010.46.11.1521831.
9
Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
Br J Pharmacol. 2011 May;163(1):53-67. doi: 10.1111/j.1476-5381.2011.01218.x.
10
[Phosphodiesterase-4 inhibitors: roflumilast].
Rev Clin Esp. 2011 Mar;211 Suppl 2:22-30. doi: 10.1016/S0014-2565(11)70008-X.
引用本文的文献
1
Roflumilast Suppresses Adipogenic Differentiation AMPK Mediated Pathway.
Front Endocrinol (Lausanne). 2021 Jun 7;12:662451. doi: 10.3389/fendo.2021.662451. eCollection 2021.
2
Roflumilast Attenuates Doxorubicin-Induced Cardiotoxicity by Targeting Inflammation and Cellular Senescence in Cardiomyocytes Mediated by SIRT1.
Drug Des Devel Ther. 2021 Jan 11;15:87-97. doi: 10.2147/DDDT.S269029. eCollection 2021.
3
A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med. 2015 Oct 15;192(8):934-42. doi: 10.1164/rccm.201503-0543OC.
4
The standardized herbal formula, PM014, ameliorated cigarette smoke-induced lung inflammation in a murine model of chronic obstructive pulmonary disease.
BMC Complement Altern Med. 2013 Sep 5;13:219. doi: 10.1186/1472-6882-13-219.
5
Bronchiectasis in older patients with chronic obstructive pulmonary disease : prevalence, diagnosis and therapeutic management.
Drugs Aging. 2013 Apr;30(4):215-25. doi: 10.1007/s40266-013-0053-4.
6
Attenuation of inhibitory prostaglandin E2 signaling in human lung fibroblasts is mediated by phosphodiesterase 4.
Am J Respir Cell Mol Biol. 2012 Dec;47(6):729-37. doi: 10.1165/rcmb.2012-0057OC. Epub 2012 Oct 4.
本文引用的文献
1
Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma.
J Allergy Clin Immunol. 2010 Dec;126(6):1252-9.e12. doi: 10.1016/j.jaci.2010.08.014. Epub 2010 Nov 3.
2
Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration.
Eur J Pharmacol. 2010 Sep 25;643(2-3):274-81. doi: 10.1016/j.ejphar.2010.06.054. Epub 2010 Jul 13.
3
The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. doi: 10.1016/j.pupt.2010.03.011. Epub 2010 Apr 7.
4
A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro.
Pulm Pharmacol Ther. 2010 Aug;23(4):283-91. doi: 10.1016/j.pupt.2010.02.004. Epub 2010 Mar 11.
5
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Lancet. 2009 Aug 29;374(9691):695-703. doi: 10.1016/S0140-6736(09)61252-6.
6
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Lancet. 2009 Aug 29;374(9691):685-94. doi: 10.1016/S0140-6736(09)61255-1.
7
Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice.
BMC Pulm Med. 2008 Aug 28;8:17. doi: 10.1186/1471-2466-8-17.
8
Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.
Bioorg Med Chem Lett. 2008 Jul 15;18(14):4237-41. doi: 10.1016/j.bmcl.2008.05.052. Epub 2008 May 17.
9
PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.
Int J Chron Obstruct Pulmon Dis. 2007;2(2):121-9.
10
Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
Eur J Pharmacol. 2007 Oct 1;571(2-3):215-21. doi: 10.1016/j.ejphar.2007.05.074. Epub 2007 Jun 16.
Zotero 插件